Latest Immunology NewsRSS

10:43 EST 20th November 2017 | BioPortfolio

STAT Plus: Pharmalittle: Roche scores two big trial wins; the secret EMA vote is today

Roche announced two clinical trial wins notably, its Tecentriq immunotherapy made advances against lung cancer when mixed with other treatments.

Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 1, 2017. The event will bring together leading expert allergists to discuss the emerging treatment landscape in peanut allergy. Topics...

STAT Plus: Roche reshuffles lung cancer immunotherapy market with positive clinical trial results

With positive results from a closely watched clinical trial announced Monday, Roche (RHHBY) is on the cusp of joining Merck (MRK) in owning an immunotherapy combination proven effective for patients…

Log in to the Live Webcast Today – 1:00 PM Eastern

Watch the LIVE WEBCAST starting at 1 pm, Eastern, Saturday, November 18, 2017 in partnership with Georgetown University Hospital, GRACE presents: 2017 Advances in Immunotherapy: What Lung Cancer Patients Need to KnowRelated Posts:

Peanut Allergy Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $2000

Peanut Allergy Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy Pipeline Review, H2 2017, provides an overview of the Peanut Allergy Immunology pipeline landscape.Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mi...

All that you leave behind

National Harbor, MD: It’s time for the first of our Gems from the Poster Halls following the Society for Immunotherapy…

Cue Biopharma Announces Strategic Research Collaboration and License Agreement with Merck

Agreement Focuses on Development of Next-Generation Biologics to Selectively Modulate T Cell Activity for the Treatment of Autoimmune Diseases Cue Biopharma™, Inc., an immunotherapy company developing a novel, proprietary class of biologics engin

OmniSYS’ John King on making a difference with the pharmacy

John KingAlthough providing immunizations is still a relatively new service line for the pharmacy, it is one that has grown rapidly in just a few short years — influenza vaccinations administered at pharmacies increased by more than 500% over a six-year time period. Yet, overall adult immunization rates in the United States remained relatively stagnant.

Getting flu shot annually has no impact on natural immunity, researchers find

Michael JohnsenResearchers at the Influenza Center in Bergen, Norway recently concluded that annual influenza vaccination does not increase susceptibility to influenza infection in years of vaccine mismatch. read more

CIRCULOGENE Introduces Single-Tube, Blood-Based Microsatellite Instability (MSI) Biomarker Testing for Multiple Cancers

MSI Diagnostic Testing Available for Precision Cancer Immunotherapy CIRCULOGENE, a leading liquid biopsy company advancing precision medicine through personalized molecular genetics testing, has announced the availability of microsatellite instability (MSI) biomarker testing for multiple cancer types. The advanced immunotherapy testing is

PIN Pharma Announces Initiation of its First Phase 1 Study

PIN Pharma today announced the initiation of a Phase 1 clinical trial for its novel immune-modulator, PIN-2. This first-in-human, proof-of-concept study is being conducted in oncology patients with solid tumors by PIN Pharma’s wholly owned Australian subsidiary, PIN Pharma Pty Ltd. The study is designed to show changes in the human immune system...

Researchers Give New Perspective on Progression from Eczema to Asthma and Allergies

Research in the AAAAI’s journal, The Journal of Allergy and Clinical Immunology (JACI), is giving new insight into the atopic march and what conditions may indicate a higher risk of further allergic disease. MILWAUKEE (PRWEB) November 15, 2017 New research in the AAAAI’s journal, The Journal of Allergy and Clinical Immunology (JACI), is giving insight into how allergic disease typically progr...

Tempus Announces Latest Immunotherapy Project

CHICAGO, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, along with Georgetown Lombardi Comprehensive Cancer Center, in Washington, D.C., and John Theurer Cancer Center at Hackensack Meridian Health Hackensack University Medical Center announce a new rese...

DBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin Peanut in the Journal of the American Medical Association

 Press Release Montrouge, France, November 14, 2017   DBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin Peanut in the Journal of the American Medical Association Primary endpoint of Phase IIb study was met after 12 months of treatment Long-term extension data showed treatment benefit increases over time Ongoi...

ImmusanT Raises $40 Million in Series C Financing

-- ARCH Venture Partners joins Vatera Healthcare Partners as Equity Investor -- -- Proceeds Will Support Phase II Study of Nexvax2®, ImmusanT’s Immunotherapy and Diagnostic for Celiac Disease -- -- Steven Gillis, Ph.D., and Thomas Daniel, M.D. join Board of Directors --

Global Veterinary Vaccine Market Data List by Segment 20152022 [Report Updated: 08112017] Prices from USD $800

SnapshotVaccines are products designed to trigger protective immune responses and prepare the immune system to fight future infections from diseasecausing agents. Vaccines stimulate the immune system's production of antibodies that identify and destroy diseasecausing organisms that enter the body. Vaccines provide immunity against one or several diseases that can lessen the severity or prevent cer...

STAT Plus: Finding a way for the ‘right’ microbiome to help cancer immunotherapy work

MD Anderson is collaborating with the Parker Institute for Cancer Immunotherapy and Seres Therapeutics to develop a cancer-targeting bacterial cocktail.

British Biotech Gets a £2.5M Grant to Boost Cancer Immunotherapy

Tusk Therapeutics is working on immunotherapies to ignite the immune system against cancer. The £2.5M grant will help it to accelerate their development. Tusk Therapeutics focuses on immuno-oncology to ‘harness the power’ of the immune system. One of its candidates ... This awesome article British Biotech Gets a £2.5M Grant to Boost Cancer Immunotherapy appeared first on

Annual Influenza Vaccination Does Not Prevent Natural Immunity

A recent study shows that there are no negative effects from having annual influenza vaccination

As the eradication of polio nears, a new crisis for global health looms

The wind-down of the Global Polio Eradication Initiative means the end of the $1 billion a year it funnels into the WHO as well as immunization efforts.

Immunomic Scientist Dr. Pratima Sinha to Speak at the International Conference on Vaccine Research and Development

Presentation to Examine the Potential of LAMP Enhancing Antitumor Immunity Tomorrow, Immunomic Therapeutics, Inc. scientist, Dr. Pratima Sinha, will present at the 3rd Annual International Conference on Vaccine Research and Development. Dr. Sinha will discuss her research employing LAMP technology in hopes of enhancing antitumor immunity. Specif...

Biotech Unicorn’s T-Cell Receptor Therapy “Nearly Doubles” Survival in Uveal Melanoma

Immunocore, one of the only three European biotech unicorns, has presented Phase I results for its TCR immunotherapy IMCgp100 in patients suffering from metastatic uveal melanoma. Results are positive, but perhaps not to the level of expectation for a company ... This awesome article Biotech Unicorn’s T-Cell Receptor Therapy “Nearly Doubles” Survival in Uveal Melanoma appeared fi...

Researchers Build a Cancer Immunotherapy Without Immune Cells

A team has engineered two stem cell lines into 'synthetic T cells' that destroy breast cancer cells in vitro.

Top 5 Things to Know About Immunotherapies – A Review

Immunotherapy – A big word with much meaning. There’s no use in talking about their history. The fact that immunotherapies seem to be the next big thing in biotech is reason enough to discuss them. For this purpose, we have ... This awesome article Top 5 Things to Know About Immunotherapies – A Review appeared first on Be kind and don't copy it without asking ;)

Nektar Stock Blows Up on Encouraging Data to Treat Difficult Cancers

The initial results were presented at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Quick Search

review and buy Immunology market research data and corporate reports here